Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling.
Comprehensive genomic profiling
JAZF1-BCORL1
Uterine adenosarcoma
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
13 Jan 2023
13 Jan 2023
Historique:
received:
25
08
2022
accepted:
19
12
2022
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
18
1
2023
Statut:
epublish
Résumé
Uterine adenosarcoma is a rare malignant tumor that accounts for 8% of all uterine sarcomas, and less than 0.2% of all uterine malignancies. However, it is frequently misdiagnosed in clinical examinations, including pathological diagnosis, and imaging studies owing to its rare and non-specific nature, which is further compounded by the lack of specific diagnostic markers. We report a case of uterine adenosarcoma for which a comprehensive genomic profiling (CGP) test provided a chance to reach the proper diagnosis. The patient, a woman in her 60s with a history of uterine leiomyoma was diagnosed with an intra-abdominal mass post presentation with abdominal distention and loss of appetite. She was suspected to have gastrointestinal stromal tumor (GIST); the laparotomically excised mass was found to comprise uniform spindle-shaped cells that grew in bundles with a herringbone architecture, and occasional myxomatous stroma. Immunostaining revealed no specific findings, and the tumor was diagnosed as a spindle cell tumor/suspicious adult fibrosarcoma. The tumor relapsed during postoperative follow-up, and showed size reduction with chemotherapy, prior to regrowth. CGP was performed to identify a possible treatment, which resulted in detection of a JAZF1-BCORL1 rearrangement. Since the rearrangement has been reported in uterine sarcomas, we reevaluated specimens of the preceding uterine leiomyoma, which revealed the presence of adenosarcoma components in the corpus uteri. Furthermore, both the uterine adenosarcoma and intra-abdominal mass were partially positive for CD10 and BCOR staining. These results led to the conclusive identification of the abdominal tumor as a metastasis of the uterine adenosarcoma. The JAZF1-BCORL1 rearrangement is predominantly associated with uterine stromal sarcomas; thus far, ours is the second report of the same in an adenosarcoma. Adenosarcomas are rare and difficult to diagnose, especially in atypical cases with scarce glandular epithelial components. Identification of rearrangements involving BCOR or BCORL1, will encourage BCOR staining analysis, thereby potentially resulting in better diagnostic outcomes. Given that platinum-based chemotherapy was proposed as the treatment choice for this patient post diagnosis with adenosarcoma, CGP also indirectly contributed to the designing of the best-suited treatment protocol.
Sections du résumé
BACKGROUND
BACKGROUND
Uterine adenosarcoma is a rare malignant tumor that accounts for 8% of all uterine sarcomas, and less than 0.2% of all uterine malignancies. However, it is frequently misdiagnosed in clinical examinations, including pathological diagnosis, and imaging studies owing to its rare and non-specific nature, which is further compounded by the lack of specific diagnostic markers.
CASE PRESENTATION
METHODS
We report a case of uterine adenosarcoma for which a comprehensive genomic profiling (CGP) test provided a chance to reach the proper diagnosis. The patient, a woman in her 60s with a history of uterine leiomyoma was diagnosed with an intra-abdominal mass post presentation with abdominal distention and loss of appetite. She was suspected to have gastrointestinal stromal tumor (GIST); the laparotomically excised mass was found to comprise uniform spindle-shaped cells that grew in bundles with a herringbone architecture, and occasional myxomatous stroma. Immunostaining revealed no specific findings, and the tumor was diagnosed as a spindle cell tumor/suspicious adult fibrosarcoma. The tumor relapsed during postoperative follow-up, and showed size reduction with chemotherapy, prior to regrowth. CGP was performed to identify a possible treatment, which resulted in detection of a JAZF1-BCORL1 rearrangement. Since the rearrangement has been reported in uterine sarcomas, we reevaluated specimens of the preceding uterine leiomyoma, which revealed the presence of adenosarcoma components in the corpus uteri. Furthermore, both the uterine adenosarcoma and intra-abdominal mass were partially positive for CD10 and BCOR staining.
CONCLUSION
CONCLUSIONS
These results led to the conclusive identification of the abdominal tumor as a metastasis of the uterine adenosarcoma. The JAZF1-BCORL1 rearrangement is predominantly associated with uterine stromal sarcomas; thus far, ours is the second report of the same in an adenosarcoma. Adenosarcomas are rare and difficult to diagnose, especially in atypical cases with scarce glandular epithelial components. Identification of rearrangements involving BCOR or BCORL1, will encourage BCOR staining analysis, thereby potentially resulting in better diagnostic outcomes. Given that platinum-based chemotherapy was proposed as the treatment choice for this patient post diagnosis with adenosarcoma, CGP also indirectly contributed to the designing of the best-suited treatment protocol.
Identifiants
pubmed: 36639698
doi: 10.1186/s13000-022-01279-4
pii: 10.1186/s13000-022-01279-4
pmc: PMC9837955
doi:
Substances chimiques
BCORL1 protein, human
0
Co-Repressor Proteins
0
DNA-Binding Proteins
0
JAZF1 protein, human
0
Repressor Proteins
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Subventions
Organisme : Japan Society for the Promotion of Science,Japan
ID : JP 20K16210
Organisme : Japan Society for the Promotion of Science,Japan
ID : JP 16H06277
Informations de copyright
© 2023. The Author(s).
Références
Cancer. 1974 Oct;34(4):1138-49
pubmed: 4371193
Biochemistry. 2020 Jul 28;59(29):2718-2728
pubmed: 32628469
Zhonghua Bing Li Xue Za Zhi. 2018 May 8;47(5):334-338
pubmed: 29783798
Int J Womens Health. 2017 Aug 31;9:597-606
pubmed: 28919822
Mod Pathol. 2021 Dec;34(12):2200-2210
pubmed: 34302054
Oncol Res Treat. 2018;41(11):693-696
pubmed: 30326467
Am J Surg Pathol. 2020 Jun;44(6):765-770
pubmed: 32011345
Hum Pathol. 1990 Apr;21(4):363-81
pubmed: 2156771
Medicine (Baltimore). 2019 Nov;98(47):e18119
pubmed: 31764852
Int J Gynecol Pathol. 1992;11(2):75-88
pubmed: 1316323
Gynecol Oncol. 1989 Sep;34(3):323-7
pubmed: 2767523
Pak J Med Sci. 2013 Jan;29(1):72-6
pubmed: 24353511
Curr Oncol Rep. 2016 Nov;18(11):68
pubmed: 27718181
Am J Surg Pathol. 2008 Jul;32(7):1013-21
pubmed: 18469708